Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
general
A televised, web-based randomised trial of an herbal remedy (Valerian) for insomnia
PLoS ONE, Volume 2, No. 10, Article e1040, Year 2007
Notification
URL copied to clipboard!
Description
Background. This trial was conducted as part of a project that aims to enhance public understanding and use of research in decisions about healthcare by enabling viewers to participate in research and to follow the process, through television reports and on the web. Valerian is an herbal over-the-counter drug that is widely used for insomnia. Systematic reviews have found inconsistent and inconclusive results about its effects. Methods. Participants were recruited through a weekly nationally televised health program in Norway. Enrolment and data collection were over the Internet. 405 participants who were 18 to 75 years old and had insomnia completed a two week diary-keeping run-in period without treatment and were randomised and mailed valerian or placebo tablets for two weeks. All participants and investigators were blind to treatment until after the analysis was completed. Findings. For the primary outcome of a minimally important improvement in self-reported sleep quality (≥:0.5 units on a 7 point scale), the difference between the valerian group (29%) and the placebo group (21%) was not statistically significant (difference 7.5%; 95% Cl-0.9 to 15.9; p=0.08). On the global self-assessment question at the end of the treatment period 5.5% (95% Cl 0.2 to 10.8) more participants in the valerian group perceived their sleep as better or much better (p = 0.04). There were similar trends favouring the valerian group for night awakenings (difference = 6.0%, 95% CI-0.5 to 12.5) and sleep duration (difference= 7.5%, 95% Cl-1.0 to 16.1). There were no serious adverse events and no important or statistically significant differences in minor adverse events. Interpretation. Based on this and previous studies, valerian appears to be safe, but with modest beneficial effects at most on insomnia compared to placebo. The combined use of television and the Internet in randomised trials offers opportunities to answer questions about the effects of health care interventions and to improve public understanding and use of randomised trials. © 2007 Oxman et al.
Authors & Co-Authors
Flottorp, Signe Agnes
Norway, Oslo
Nasjonalt Kunnskapssenter for Helsetjenesten
Fretheim, Atle
Norway, Oslo
Nasjonalt Kunnskapssenter for Helsetjenesten
Austvoll-Dahlgren, Astrid
Norway, Oslo
Nasjonalt Kunnskapssenter for Helsetjenesten
Pallesen, Ståle
Norway, Bergen
Haukeland Universitetssjukehus
Norway, Bergen
Universitetet I Bergen
Bjorvatn, Björn
Norway, Bergen
Haukeland Universitetssjukehus
Norway, Bergen
Universitetet I Bergen
Statistics
Citations: 54
Authors: 5
Affiliations: 3
Identifiers
Doi:
10.1371/journal.pone.0001040
ISSN:
19326203
Research Areas
Disability
Health System And Policy
Study Design
Grounded Theory